First Turn Management’s Enliven Therapeutics ELVN Stock Holding History

First Turn Management’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.5M	Buy	+623,839	New	+$17.3M	2.73%	15
2025 Q4	–	Sell	-783,411	Closed	-$16M	–	37
2025 Q3	$16M	Buy	783,411 +273,424	+54%	+$5.51M	2.41%	19
2025 Q2	$10.2M	Sell	509,987 -25,105	-5%	-$475K	1.91%	25
2025 Q1	$10.5M	Hold	535,092	–	–	2.12%	25
2024 Q4	$12M	Hold	535,092	–	–	2.16%	22
2024 Q3	$13.7M	Buy	535,092 +121,849	+29%	+$2.82M	2.16%	26
2024 Q2	$9.66M	Buy	+413,243	New	+$8.7M	1.57%	34

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Turn Management's ELVN Position: Q1 2026 in Review

First Turn Management opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 623,839 shares worth $24.5M. The stake represents 2.73% of the portfolio and ranks #15 among its holdings. This is a return to the name: First Turn Management previously reported a position in ELVN as recently as Q3 2025.

First Turn Management first reported a position in ELVN in Q2 2024 and has held it in 7 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

First Turn Management held 623,839 shares of Enliven Therapeutics worth $24.5M as of Q1 2026.
Enliven Therapeutics was a new First Turn Management position in Q1 2026.
Enliven Therapeutics made up 2.73% of First Turn Management's portfolio in Q1 2026, its #15 holding.
First Turn Management first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 7 quarters since.
170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on First Turn Management's 13F filing for Q1 2026, filed 15 May 2026.